PubMed Health⌕ Search

PubMed · 8537832

Drug profiles: maximizing therapeutic effectiveness.

Abstract

Major cardiac events are inevitably followed with a pharmacologic plan of therapy for cardiac patients. Careful assessment of the patient's drug regimen is an important aspect of cardiovascular nursing practice. Such assessment will reveal implications for education, compliance counseling, and side effect evaluation. A thorough drug history should include information about both prescription and nonprescription drug use. Assessment for adherence is improved by using supportive, open-ended questions. Assessment for side effects that affect quality of life is important, particularly in the area of sexual dysfunction. Sexual function should be assessed before beginning cardiovascular drug therapy and monitored for changes during treatment. Using principles of chronopharmacology, or therapy based on the time-dependent effects of drugs, nurses can schedule cardiovascular medications and evaluate patient responses in relation to circadian variability in vulnerability and symptoms. Assessment for ease of self-management of the drug regimen should be a particular focus with non-English-speaking patients and those with complex or costly drug regimens.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L A Porter, S B Dunbar. 1995. Drug profiles: maximizing therapeutic effectiveness.. https://doi.org/10.1097/00005082-199510000-00006

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Cardiovascular therapy and pharmacogenetics in 2007.

John Carlquist received a PhD from the Department of Cellular Viral and Molecular Biology at the University of Utah School of Medicine (UT, USA) with research emphasis in molecular immunology. After completion of his training, he received a faculty appointment in the Department of Internal Medicine, University of Utah, where he became interested in immune mechanisms in cardiovascular disease. He developed an interest in genetics through studies of human leukocyte antigen (HLA) associations with idiopathic dilated cardiomyopathy and rheumatic heart disease. He began the Molecular Diagnostics Laboratory for Intermountain Healthcare and continues to serve as Technical Director; he also directs the Intermountain Heart Study Molecular and Genetic Research Laboratory. Current research interests include the genetics of lipid metabolism as related to coronary heart disease and the genetic factors influencing drug treatment outcomes.

Cardiovascular Agents↗

Ensuring that patients receive full cardiac pharmacotherapy services: a pharmacist's call to arms.

While clinical trials have proven that use of certain cardiovascular drugs improves morbidity and mortality, these drugs are not widely used, they are by and large prescribed in suboptimal doses, and their benefit is further diminished by nonadherence. Pharmacists have the ability to improve the survival of patients with cardiovascular risks. This can only be accomplished through the efforts of the individual pharmacist and the further development of health-system management services. Pharmacists need to leverage their access to patients, their large patient base, and their knowledge of refill dates to improve patient care. Support and development of more pharmacist-directed anticoagulation, hyperlipidemia, and hypertension clinics are also needed.

Cardiovascular Agents↗